SuperworthTranscode Therapeutics EPS RNAZ
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- −$7.17
- Fiscal year 2022
- −$1005681.60
Transcode Therapeutics' twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was −$7.17.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2022 | −$1005681.60 | n/a |
| FY2021 | −$650496.00 | n/a |
| FY2020 | −$376992.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$7.17 | n/a | n/a | |
| Q1 FY26 | −$21.28 | n/a | n/a | |
| Q3 FY25 | −$5.82 | n/a | n/a | |
| Q2 FY25 | −$5.13 | n/a | n/a | |
| Q1 FY25 | −$70.16 | n/a | n/a | |
| Q3 FY24 | −$146.06 | n/a | n/a | |
| Q2 FY24 | −$680.23 | n/a | n/a | |
| Q1 FY24 | −$597.80 | n/a | n/a | |
| Q3 FY23 | −$44758.56 | n/a | −$711378.36 | |
| Q2 FY23 | −$131559.12 | n/a | −$910925.40 | |
| Q1 FY23 | −$239380.68 | n/a | −$1045478.28 | |
| Q4 FY22 | −$295680.00 | n/a | −$1005681.60 |
Against its peers
Companies in Drug Manufacturers - General nearest Transcode Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| RNAZTranscode Therapeutics | n/m | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Transcode Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.